Peptides

Type "peptides for IBS" into any search engine and you will find forums full of people reporting dramatic results from BPC-157, along with a handful of wellness sites citing "gut-healing research" as justification. The biological story sounds plausible — BPC-157 demonstrably reduces intestinal inflammation in rat models, and IBS involves gut dysfunction, so the implied […]

Long COVID does not have a single approved treatment. That sentence is not pessimism — it is the state of a condition that the NIH spent more than a billion dollars studying and still cannot reliably reverse. Into that gap, wellness content has pushed BPC-157 and thymosin alpha-1 as "immune-modulating" peptides that might address what

If you search "peptides for perimenopause" right now, the results split into two camps that could not be further apart in terms of evidence: on one side, FDA-approved injectable GLP-1 receptor agonists with large randomized trial data on weight and metabolic outcomes; on the other, a broad category of unregulated peptide products making claims about

WeightWatchers was supposed to be the brand that GLP-1 drugs destroyed. A company built entirely on behavioral change, on counting points and logging steps and meeting in church basements, suddenly competing against a weekly injection that produces three times the weight loss. Instead of retreating, WeightWatchers spent $132 million to acquire a GLP-1 prescribing platform

Hims & Hers launched GLP-1 prescriptions in May 2024 at $199 per month and built $225 million in revenue from that business in a single calendar year — on a legal window that closed in October 2024 when the FDA removed semaglutide from its shortage list. The compounding business that powered that growth attracted two

Ro GLP-1 Telehealth Review: Inside Roman / Rory's Weight-Loss Program When Roman started prescribing erectile dysfunction medication online in 2017, it looked like a single-category bet. Seven years later, the company behind Roman, Rory, and the Zero smoking cessation brand has quietly become one of the largest GLP-1 telehealth platforms in the country, writing prescriptions

Found is one of the larger GLP-1 telehealth platforms in the U.S., and it markets itself on breadth: more than ten medications, insurance partnerships across most states, and behavioral coaching woven into the subscription. On paper that sounds thorough. In practice the experience depends heavily on whether your insurance cooperates, which drug your clinician selects,

The list price on a GLP-1 prescription can hit your inbox before the ink is dry on your diagnosis, and the number is startling: somewhere between $900 and $1,400 per month at the pharmacy counter, depending on the drug and the dose. What that sticker price has to do with what you will actually pay

Self-injecting a GLP-1 medication for the first time can feel strangely high-stakes — and in some ways it is, because the pen in your hand delivers a precise dose of an FDA-approved prescription drug, not a supplement. Ozempic, Wegovy, Mounjaro, and Zepbound are each independently reviewed and approved by the FDA under separate New Drug

If you've been researching peptides and noticed that the label on a collagen powder looks nothing like the label on a compounded injectable, which looks nothing like the insert inside a branded GLP-1 pen, the short answer is: those three formats operate under entirely different regulatory frameworks, and they communicate completely different things. Confusing one